Wells Fargo analyst Derek Archila has maintained their bullish stance on ARGX stock, giving a Buy rating today.
Derek Archila has given his Buy rating due to a combination of factors related to Argenx Se’s promising outlook. The sales momentum of Vyvgart, a key product, is expected to continue into 2025, with potential modest upside to estimates. This is supported by the anticipated approval for new patient use and increased adoption by new doctors, particularly following the CIDP launch.
Additionally, while there are no major readouts for Vyvgart trials this year, positive data from ongoing studies could enhance the perceived value of Vyvgart’s expansion opportunities. The company’s broader pipeline also holds promise, with upcoming data from trials like empasi’s DGF and ARGX-119’s CMS POC expected to attract investor interest. These factors, combined with a revised price target based on higher revenue forecasts, underpin the Buy rating.
In another report released today, JMP Securities also reiterated a Buy rating on the stock with a $701.00 price target.
ARGX’s price has also changed moderately for the past six months – from $516.640 to $624.700, which is a 20.92% increase.